, Columnist
Merck Extends Its Lung Cancer Lead
Sales of Keytruda may begin ticking up immediately as doctors react to the results.
This article is for subscribers only.
It's a bit late for Christmas, but Merck & Co. just gave investors a gift.
The company announced on Monday that a combination of its key immune-boosting cancer drug Keytruda and an older chemotherapy helped newly diagnosed lung cancer patients survive significantly longer in a large trial -- a groundbreaking result that comes months earlier than expected.